XML 36 R4.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Revenues      
Revenues $ 103,178 $ 90,722 $ 151,178
Operating Expenses      
Impairment of goodwill 9,635 87,862 0
Impairment of other noncurrent assets 13,326 32,627 60,504
Other Expense, Net      
Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net (106) 7,833 (30,200)
Equity in net loss of affiliates (1,176) (6,730) (11,608)
Loss from continuing operations before income taxes (103,855) (171,264) (395,912)
Income tax benefit 82 930 15,425
Loss from discontinued operations, net of income tax benefit (66,748) (153,582) (134,219)
Net loss (170,521) (323,916) (514,706)
Net loss attributable to the noncontrolling interests 0 1,592 5,370
Net loss attributable to Precigen (170,521) (322,324) (509,336)
Amounts Attributable to Precigen      
Net loss from continuing operations attributable to Precigen (103,773) (168,742) (375,117)
Net loss from discontinued operations attributable to Precigen (66,748) (153,582) (134,219)
Net loss attributable to Precigen $ (170,521) $ (322,324) $ (509,336)
Net Loss per Share      
Net loss from continuing operations attributable to Precigen per share, basic and diluted (in usd per share) $ (0.62) $ (1.09) $ (2.90)
Net loss from discontinued operations attributable to Precigen per share, basic and diluted (in usd per share) (0.40) (1.00) (1.03)
Net loss attributable to Precigen per share, basic and diluted (in usd per share) $ (1.02) $ (2.09) $ (3.93)
Weighted average shares outstanding, basic and diluted (in shares) 167,065,539 154,138,774 129,521,731
Collaboration and licensing agreements      
Revenues      
Revenues $ 21,208 $ 14,059 $ 69,540
Continuing Operations      
Revenues      
Revenues 103,178 90,722 151,178
Operating Expenses      
Research and development 41,644 66,666 333,007
Selling, general and administrative 91,704 98,634 125,162
Impairment of goodwill 0 29,820 0
Impairment of other noncurrent assets 920 990 0
Total operating expenses 189,781 257,511 520,845
Operating loss (86,603) (166,789) (369,667)
Other Expense, Net      
Unrealized and realized appreciation (depreciation) in fair value of equity securities and preferred stock, net 0 8,291 (28,273)
Interest expense (18,400) (17,666) (8,473)
Interest and dividend income 2,451 3,871 19,017
Other income (expense), net (165) 3,445 470
Total other expense, net (16,114) (2,059) (17,259)
Equity in net loss of affiliates (1,138) (2,416) (8,986)
Loss from continuing operations before income taxes (103,855) (171,264) (395,912)
Income tax benefit 82 930 15,425
Loss from continuing operations (103,773) (170,334) (380,487)
Continuing Operations | Collaboration and licensing agreements      
Revenues      
Revenues 21,208 14,059 69,540
Continuing Operations | Product revenues      
Revenues      
Revenues 24,349 23,780 28,486
Operating Expenses      
Cost of product and services 28,550 31,930 35,087
Continuing Operations | Service revenues      
Revenues      
Revenues 56,899 51,803 52,419
Operating Expenses      
Cost of product and services 26,963 29,471 27,589
Continuing Operations | Other revenues      
Revenues      
Revenues $ 722 $ 1,080 $ 733